Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

Overview of attention for article published in Lancet Oncology, August 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

policy: 1 policy source
twitter: 5 X users
patent: 3 patents

facebook: 2 Facebook pages
f1000: 1 research highlight platform

Citations

dimensions_citation: 1079 Dimensions

Readers on

mendeley: 779 Mendeley

Summary Policy documents X Patents Facebook Research highlights Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

USE OF SIMULTANEOUS MARKER DETECTION FOR ASSESSING DIFUSE GLIOMA AND RESPONSIVENESS TO…

Application EP-4041921-A4

European Patent Office

Combination of immunotherapy with local chemotherapy for the treatment of malignancies

Grant US-11779555-B2

United States of America

Combination of immunotherapy with local chemotherapy for the treatment of malignancies

Grant US-10864180-B2

United States of America

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.